Cargando…
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967473/ https://www.ncbi.nlm.nih.gov/pubmed/27493970 http://dx.doi.org/10.1155/2016/2909436 |
_version_ | 1782445521797906432 |
---|---|
author | Samoš, Matej Fedor, Marián Kovář, František Galajda, Peter Bolek, Tomáš Stančiaková, Lucia Fedorová, Jana Staško, Ján Kubisz, Peter Mokáň, Marián |
author_facet | Samoš, Matej Fedor, Marián Kovář, František Galajda, Peter Bolek, Tomáš Stančiaková, Lucia Fedorová, Jana Staško, Ján Kubisz, Peter Mokáň, Marián |
author_sort | Samoš, Matej |
collection | PubMed |
description | Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67 patients were enrolled. 21 patients had T2D. Among all study population, 33 patients received clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor blocker therapy had been tested in two time intervals using light transmission aggregometry with specific inducer and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant differences in platelet aggregability among T2D and nondiabetic (ND) group. The platelet reactivity index of VASP-P did not differ significantly between T2D and ND group (59.4 ± 30.9% versus 60.0 ± 25.2% and 33.9 ± 25.3% versus 38.6 ± 29.3% in second testing). The number of ADP receptor blocker nonresponders did not differ significantly between T2D and ND patients. The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations. Conclusion. This prospective study did not confirm the higher platelet reactivity and higher prevalence of ADP receptor blocker nonresponders in T2D acute STEMI patients. |
format | Online Article Text |
id | pubmed-4967473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-49674732016-08-04 The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study Samoš, Matej Fedor, Marián Kovář, František Galajda, Peter Bolek, Tomáš Stančiaková, Lucia Fedorová, Jana Staško, Ján Kubisz, Peter Mokáň, Marián J Diabetes Res Research Article Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67 patients were enrolled. 21 patients had T2D. Among all study population, 33 patients received clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor blocker therapy had been tested in two time intervals using light transmission aggregometry with specific inducer and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant differences in platelet aggregability among T2D and nondiabetic (ND) group. The platelet reactivity index of VASP-P did not differ significantly between T2D and ND group (59.4 ± 30.9% versus 60.0 ± 25.2% and 33.9 ± 25.3% versus 38.6 ± 29.3% in second testing). The number of ADP receptor blocker nonresponders did not differ significantly between T2D and ND patients. The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations. Conclusion. This prospective study did not confirm the higher platelet reactivity and higher prevalence of ADP receptor blocker nonresponders in T2D acute STEMI patients. Hindawi Publishing Corporation 2016 2016-07-17 /pmc/articles/PMC4967473/ /pubmed/27493970 http://dx.doi.org/10.1155/2016/2909436 Text en Copyright © 2016 Matej Samoš et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Samoš, Matej Fedor, Marián Kovář, František Galajda, Peter Bolek, Tomáš Stančiaková, Lucia Fedorová, Jana Staško, Ján Kubisz, Peter Mokáň, Marián The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
title | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
title_full | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
title_fullStr | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
title_full_unstemmed | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
title_short | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
title_sort | impact of type 2 diabetes on the efficacy of adp receptor blockers in patients with acute st elevation myocardial infarction: a pilot prospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967473/ https://www.ncbi.nlm.nih.gov/pubmed/27493970 http://dx.doi.org/10.1155/2016/2909436 |
work_keys_str_mv | AT samosmatej theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT fedormarian theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT kovarfrantisek theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT galajdapeter theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT bolektomas theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT stanciakovalucia theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT fedorovajana theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT staskojan theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT kubiszpeter theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT mokanmarian theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT samosmatej impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT fedormarian impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT kovarfrantisek impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT galajdapeter impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT bolektomas impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT stanciakovalucia impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT fedorovajana impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT staskojan impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT kubiszpeter impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT mokanmarian impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy |